Total revenue, net, decreased by $15.0 million (7%) to $213.6 million in 2025 from $228.6 million in 2024. U.S. product revenue, net, declined by 8% to $154.1 million in 2025 from $166.7 million in 2024, primarily due to a decrease in net selling price from generic competition. Amarin's share of the U.S. icosapent ethyl market decreased to approximately 47% in 2025 from 53% in 2024, despite the overall market increasing by 2%. VASCEPA-branded prescriptions in the U.S. decreased by 10% in 2025 compared to 2024. Licensing and royalty revenue increased by $6.9 million (29%) to $30.9 million in 2025, primarily due to a $25.0 million upfront payment from the Recordati Licensing Agreement. Cost of goods sold decreased by $54.5 million (37%) to $92.8 million in 2025, partly due to a $36.5 million restructuring inventory charge in 2024 not recurring at the same magnitude in 2025. Gross margin on product sales improved to 49% in 2025 from 28% in 2024 (excluding restructuring inventory and write-off charges, gross margin was 49% in 2025 and 50% in 2024). Selling, general and administrative expense decreased by $37.3 million (24%) to $115.0 million in 2025, mainly due to cost reductions from the Global Restructuring Plan. Research and development expense decreased by $1.1 million (5%) to $19.8 million in 2025. A global restructuring plan was announced in June 2025, expected to reduce operating costs by approximately $70 million annually, primarily from eliminating European commercial roles. Net loss for 2025 was $38.8 million, compared to $82.2 million in 2024 and $59.1 million in 2023. Cash and cash equivalents and short-term investments totaled $302.6 million as of December 31, 2025. The company has an accumulated deficit of $1.7 billion as of December 31, 2025. VASCEPA/VAZKEPA has received marketing authorization and is being commercialized or is under regulatory review in numerous countries outside the U.S., including Europe, Canada, China, Australia, New Zealand, Middle East, North Africa, South Korea, and Israel. In Europe, VAZKEPA has 10 years of market protection, with a patent issued in April 2024 extending exclusivity to 2039. The U.S. Supreme Court granted Hikma's petition to review a Federal Circuit decision regarding patent infringement litigation, staying District Court proceedings. Amarin is a defendant in six antitrust class action lawsuits and is cooperating with DOJ and New York Attorney General investigations related to promotional speaker programs and co-payment waiver programs.